Toxicity, Not Relapse, Drives Infant Soft Tissue Tumor Survival Gap

A Canadian study reveals that infants under one year old have lower survival rates for soft tissue tumors compared to older children, primarily due to treatment-related toxicity rather than cancer relapse. The findings suggest a need for specialized care approaches for the youngest patients.
Why it matters
This research identifies a critical gap in pediatric oncology outcomes, pointing toward the need for less toxic treatment protocols for infants.
Infants younger than 1 year with bone and soft tissue tumors had poorer survival than children aged 1 to 10 years despite no greater risk of relapse, a gap largely explained by a 4-fold higher risk of treatment-related mortality (TRM), according to a Canadian population-based study published in Pediatric Blood & Cancer.1 After accounting for tumor type and metastases, infancy remained independently associated with worse overall survival (OS), with an adjusted HR of 1.61 (95% CI, 1.13-2.31; P = .009).
Infants also developed a different mix of tumors than older children. Malignant rhabdoid tumors (MRT) made up more than a quarter of infant cases vs less than 3% in older children.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in